OrganoClick

* Q3 soft, lower volumes from two major customers* We cut '26e-'27e sales and EBIT by 6% and SEK 6m, respectively* Expect volume recovery to take longer than initially projectedQ3 challenging, but cost savings aheadQ3 sales were lower than expected at...

* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.9m)* Lower volumes from two major customers due to timing effects* Cost savings program of ~SEK 14m announcedQ3 resultsSales came in lower than expected at SEK 22m (-18% vs. ABGSCe 27m), -22%...

* Report out on 5 November* Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m)* GC&MP the bright spot, other segments under pressureQ3 expectationsQ3 marks the beginning of the second half of the year, which is typically weaker for OrganoClick (particularly...

Q2 figures pre-announced OrganoClick reported sales of SEK 30m (-23% y-o-y) and EBIT of -4.7m (-0.1m), in line with the 11 July profit warning. The miss was broad-based compared to estimates from our preview (pre-PW). NW&FT sales were -28% vs. ABGSCe...

Q2 figures in line with pre-announcement The Q2 figures were in line with the profit warning issued on 11 July, i.e. sales of SEK 30m (-23% y-o-y) and an EBIT of SEK -4.7m (-0.1m). FW sales were, as pre-announced in the PW, SEK 10.6m (-34% y-o-y). Sales...

- Q2 sales SEK 30m, EBIT -4.7m (vs. ABGSCe 37m and -0.4m) - Costs savings of SEK 3m per year from Q4 - Cash balance SEK 2m in Q2, 10m loan booked in Q3 Sales and EBIT miss of SEK 7m and 4m vs. ABGSCe This morning, OrganoClick issued a PW and presented...

- Report out 18 July - Q2e: sales SEK 37m, -3% y-o-y, EBIT SEK -0.1m - Headwinds in NW&FT and FW, good momentum in GC&MP Q2 expectations We estimate Q2 sales of SEK 37m, -3% y-o-y and +6% q-o-q. We expect GC&MP will remain the growth driver (+9% y-o-...